VCBeat Health Contact Us
Home Merck Announces FDA Acceptance of Supplemental New Drug Application for WELIREG with Priority Review for Advanced Renal Cell Carcinoma

Merck Announces FDA Acceptance of Supplemental New Drug Application for WELIREG with Priority Review for Advanced Renal Cell Carcinoma

Sep 19, 2023 19:06 CST Updated 19:06
Merck Group

Pharmaceutical R&D Developer

FDA

U.S. Food and Drug Administration

Merck Announces FDA Acceptance and Priority Review of sNDA for WELIREG (HIF-2α Inhibitor) in Advanced RCC